Graham Foster

Title: Professor
Professor of Hepatology

Professor Foster is the Professor of Hepatology at  Queen Mary University of London and a consultant at Barts Health Trust. He trained in Medicine at Oxford and London Universities in the 1980s and completed a PhD in Molecular Biology in 1992.  Professor Foster has a long standing interest in the management of chronic viral hepatitis and runs a clinical research program studying the natural history of viral hepatitis, its impact upon patients and their communities and novel therapies for this disease. He supervises a laboratory research program investigating the basic virology of hepatotropic viruses novel replication models for hepatitis C.  He is the sub-editor of The Journal of Viral Hepatitis and has published widely in the field of viral liver disease. He is President of BASL, Vice Chairman the UK Department of Health Advisory Group on Hepatitis and a member of a number of patient advocacy groups.

Research

Virology of hepatotrophic viruses including hepatitis B and hepatitis C.

Liver inflammation and its sequelae

Clinical impact of chronic viral hepatitis at the individual and population level

Access to difficult to reach patient groups, particularly those suffering from viral hepatitis

New drug regimes for patients with chronic viral hepatitis

Publications

Foster GR, Hézode C, Bronowicki JP, Carosi G, Weiland O, Verlinden L, van Heeswijk R, van Baelen B, Picchio G, Beumont M. Telaprevir Alone or With Peginterferon and Ribavirin Reduces HCV RNA in Patients With Chronic Genotype 2 But Not Genotype 3 Infections. Gastroenterology. 2011;141:881-889

 

Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M; REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011 Jun 23;364(25):2417-28

 

G Uddin, D Shoeb, S Solaiman, R  Marley, C Gore,M Ramsay,R Harris,I Ushiro-Lumb, S Moreea,S Alam,HC Thomas,S Khan, B Watt, RN Pugh, S Ramaiah , R  Jervis, A Hughes, S. Singhal, S Cameron, WF Carman,GR Foster

Prevalence of chronic viral hepatitis in people of  south Asian ethnicity living in England: the prevalence can not necessarily be predicted from the prevalence in the country of origin J Viral Hepatitis 2010;17:327-35

 

Zeuzem S, Buggisch P, Agarwal K, Marcellin P, Sereni D, Klinker H, Moreno C, Zarski JP, Horsmans Y, Mo H, Arterburn S, Knox S, Oldach D, McHutchison JG, Manns MP, Foster GR The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.Hepatology. 2012 Mar;55(3):749-58


Contact

PA:

Mrs Anna Alongi

Tel: 020 7882 7241, E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

020 7882 7242
This email address is being protected from spambots. You need JavaScript enabled to view it.